Clinical trials
Crohn’s disease clinical trials
A type of inflammatory bowel disease causing inflammation of the digestive tract. We’re tracking 334 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
San Francisco, CaliforniaAges 2–19 - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Phoenix, ArizonaAges 2–17 - NCT05428345Recruiting
Shot of vedolizumab skin injection for active bowel inflammation
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT07123207Recruiting
Probiotic with infliximab for Crohn's disease
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Changsha, HunanAges 18–75 - NCT07606339Recruiting
Guselkumab for moderate-to-severe Crohn's or ulcerative colitis
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
ViennaAges 18 years+ - NCT03681652Recruiting
Study of recovery outcomes after Crohn’s surgery in children
This study looks at outcomes after children with Crohn’s disease have part of the bowel removed (ileo-cecal resection). It may help doctors improve post-surgery care, especially for preventing flare-ups in the months after surgery.
Petah Tikva, IsraelAges 6–18 - NCT04372108Recruiting
Long-term safety study for ustekinumab vs other biologics
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
Portsmouth, VirginiaAges 18 years+ - NCT04803916Recruiting
Balloon dilation study for Crohn’s bowel strictures
This study looks at inflammation just before a narrowed section of the bowel in people with Crohn’s disease, using planned endoscopic balloon dilation. It may help doctors better understand what drives narrowing and inflammation so treatment can be timed and chosen more effectively.
JerusalemAges Any age - NCT05502965Recruiting
Diet pattern trial for Crohn’s after bowel surgery
This study tests whether a specific diet after Crohn’s surgery can help you recover and stay well. It compares outcomes in people who can follow an exact diet plan after bowel resection.
Hangzhou, ZhejiangAges 14 years+ - NCT05725876RecruitingPhase 1
Imaging ustekinumab medicine movement in Crohn’s and psoriasis
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
GroningenAges 18 years+ - NCT06727253Recruiting
Glycan supplement study for Crohn's disease after surgery
This trial tests whether a glycan supplement can prevent Crohn's disease from coming back after surgery to remove the diseased part of the small and large intestine. It may help people who have had this specific surgery and are not taking certain other treatments.
Lisbon, Lisbon DistrictAges 18–75 - NCT07303686RecruitingPhase 4
Reducing Stelara dose in Crohn's and colitis remission
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
Montreal, QuebecAges 18 years+ - NCT07510191RecruitingPhase 4
Comparing two ways to treat Crohn's disease if TNFi isn't working well
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Guangzhou, GuangdongAges 18–65 - NCT06298461RecruitingPhase 4
Comparing bowel preps for Crohn's and colitis patients
This trial compares two different bowel preparation solutions (2L-PEG and oral sulfate solution) for people with Crohn's disease or ulcerative colitis who are having a colonoscopy. The goal is to find which preparation works better and is more comfortable for patients with these conditions.
Winnipeg, ManitobaAges 18 years+ - NCT06152289Recruiting
Better diagnosis with capsule endoscopy images
This trial uses images and videos from routine capsule endoscopy procedures to develop better ways to diagnose conditions. If you're already scheduled for a capsule endoscopy, you can help by allowing your images to be used for research.
ParisAges Any age - NCT07242248Recruiting
Real-world study of guselkumab for Crohn's and colitis
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
HarrowAges 18 years+ - NCT07487480Recruiting
Guselkumab for Crohn's after ustekinumab
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06655415Recruiting
Study for family members at risk of inflammatory bowel disease
This study follows people who have a parent, sibling, or child with Crohn's disease or ulcerative colitis to help understand why some family members develop the condition. If you are 14 or older and do not already have IBD, you may be able to join.
Boston, MassachusettsAges 14 years+ - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT07775352Recruiting
Ultrasound-guided care for inflammatory bowel disease
This study tests whether using ultrasound to guide treatment can help manage inflammatory bowel disease. You may join if you are having an endoscopy to assess your disease.
BangkokAges 18 years+ - NCT07769437Recruiting
Sweetener study for crohn's disease in remission
This study looks at how non-nutritive sweeteners (like those in diet drinks) affect people with Crohn's disease who are currently in remission. By tracking what you eat and your symptoms, researchers hope to learn if these sweeteners influence disease activity.
Chagrin Falls, OhioAges 18–70 - NCT06560021Enrolling by invitation
Random biopsies in inflammatory bowel disease surveillance
This trial looks at whether taking random biopsies during a routine colonoscopy is helpful for people with inflammatory bowel disease (IBD) who are at risk for colon cancer. It aims to understand if random biopsies can detect early signs of cancer or pre-cancer.
Birmingham, AlabamaAges 18 years+ - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80 - NCT07034664Recruiting
Ultrasound to predict Guselkumab response in Crohn's disease
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
Changsha, HunanAges 18–80
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for crohn’s disease?
- Yes. Clin2 currently lists 334 recruiting crohn’s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a crohn’s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a crohn’s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.